online pharmacy, prescription drugs online



Drugs online research references









  • Nephrectomy, converting enzyme inhibition, and angiotensin peptides.
  • Inhibition of converting enzyme in the cerebrospinal fluid of rats after oral treatment with converting enzyme inhibitors.
  • Functional activity and expression of the myocardial postreceptor adenylyl cyclase system in pressure overload hypertrophy in rat.
  • Cardiovascular effects of felodipine are not antagonized by dietary salt.
  • Felodipine inhibits free-radical production by cytokines and glucose in human smooth muscle cells.
  • The effects of ramipril on glucose tolerance, insulin secretion, and insulin sensitivity in patients with hypertension.
  • Global and regional hemodynamic effects of ramipril in congestive heart failure.
  • Effects of ramipril on the hormone concentrations in serum of hypertensive patients.
  • Effects of hypercholesterolemia on the contractions to angiotensin II in the isolated aorta and iliac artery of the rabbit: role of arachidonic acid metabolites.
  • Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism.
  • Infarct size limiting effect of apstatin alone and in combination with enalapril, lisinopril and ramipril in rats with experimental myocardial infarction.
  • Diabetic vascular hypertrophy and albuminuria: effect of angiotensin converting enzyme inhibition.
  • Functional impact of an increase in ventricular mass after myocardial damage and its attenuation by converting enzyme inhibition.
  • Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition.
  • Effect of ramipril, an inhibitor of angiotensin converting enzyme, on the response of rat thoracic aorta to injury with a balloon catheter.
  • Converting enzyme inhibitor-stimulated formation of nitric oxide and prostacyclin in endothelial cells from bovine aorta is mediated by endothelium-derived bradykinin.
  • Mnemogenic effects of injecting RA-octil, a CE-inhibitor derivate, systemically or into the basal forebrain.
  • Glomerular filtration rate in early experimental diabetes.
  • Analysis of ACE inhibitors in pharmaceutical dosage forms by derivative UV spectroscopy and liquid chromatography (HPLC).
  • Spectral analysis of intercycle heart fluctuations in the diethyl-ether-anaesthetized or pithed rat treated with prazosin, dl-propranolol, endothelin-1, alpha-r atriopeptin and ACE-inhibitors.
  • Chronic angiotensin-converting enzyme inhibition and endothelial function of rat aorta.
  • The effects on cardiac arrhythmias of antihypertensive therapy causing regression of left ventricular hypertrophy.
  • Levels of brain angiotensin in the spontaneously hypertensive rat and treatment with ramiprilat.
  • Effect of angiotensin-converting enzyme inhibition on human tissue renin.
  • Effects of Ramipril and Isradipin on hemorheological profiles in patients with arterial hypertension.
  • Amlodipine promotes kinin-mediated nitric oxide production in coronary microvessels of failing human hearts.
  • Atrial natriuretic peptide levels in congestive heart failure in man before and during converting enzyme inhibition.
  • Nephroprotection by long-term ACE inhibition with ramipril in spontaneously hypertensive stroke prone rats.
  • The effect of ramipril on metabolic, renal and cardiac function in hypertension and type II diabetes mellitus
  • Bioenergetics of liver mitochondria after administration of ramipril in experimental diabetes mellitus
  • L-type calcium channels modulate the regression of left ventricular hypertrophy after ace-inhibition in genetic hypertension.
  • Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy: effects of angiotensin converting enzyme inhibition.
  • Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits.
  • CE inhibition and natriuresis with ramipril in conscious SHR: different modes of action of loop and thiazide diuretics.
  • Renin vs. angiotensin-converting enzyme inhibition in the rat: consequences for plasma and renal tissue angiotensin.
  • ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption.
  • Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors.
  • Evidence for stimulation of neutrophil degranulation by selected angiotensin converting enzyme inhibitors in vitro.
  • Effect of an angiotensin-converting enzyme inhibitor on blood pressure and erythropoiesis in rats.
  • Sub-antihypertensive doses of ramipril normalize sarcoplasmic reticulum calcium ATPase expression and function following cardiac hypertrophy in rats.
  • ACE inhibition: mechanisms of "cardioprotection" in acute myocardial ischemia
  • No evidence for involvement of angiotensin II in spatial learning in water maze in rats.
  • Intra-arterial application of the ACE inhibitor ramipril using a microperforated catheter for the prevention of neointimal proliferation after angioplasty in an animal model
  • Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells.
  • Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation.
  • Ramiprilat prevents PAF-induced myocellular and endothelial injury in a neutrophil-perfused heart preparation.
  • Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV).
  • Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles.
  • The inhibition of angiotensin converting enzyme attenuates the effects of chronic hypoxia on pulmonary blood vessels in the rat.
  • Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus.
  • ACE inhibitors in HF restore canine pulmonary endothelial function and ANG II vasoconstriction.
  • Long-term low-dose angiotensin converting enzyme inhibitor treatment increases vascular cyclic guanosine 3',5'-monophosphate.
  • Haemodynamic mechanisms of corticotropin (ACTH)-induced hypertension in the rat.
  • The lipophilic properties of angiotensin I-converting enzyme inhibitors do not influence their diffusion through cultured endothelium.
  • Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients.
  • ACE Inhibitors and Renal Vascular Responses in the Spontaneously Hypertensive Rat.
  • Local inhibition of angiotensin II formation and bradykinin degradation in isolated hearts.
  • Synergy of amlodipine and angiotensin-converting enzyme inhibitors in regulating myocardial oxygen consumption in normal canine and failing human hearts.
  • Clinical study of the month. The HOPE study, a two-by-two factorial clinical trial with contrasted results
  • The urinary bladder angiotensin system: response to infusions of angiotensin I and angiotensin-converting enzyme inhibitors.
  • Oxygen radical system in chronic infarcted rat heart: the effect of combined beta blockade and ACE inhibition.
  • Expression of cardiac angiotensin II AT1 receptor genes in rat hearts is regulated by steroids but not by angiotensin II.
  • Ramipril increases the protein level of skeletal muscle IRS-1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive rats.
  • Influence of the British Columbia reference drug program on hospital formularies: a survey of hospital pharmacy managers.
  • Urapidil effects on oxidative stress in hypertensive crises
  • Recommendations for the management of special populations: racial and ethnic populations.
  • Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II.
  • Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
  • Effect of ramipril, a new angiotensin converting enzyme inhibitor, on diurnal variations of blood pressure in essential hypertension.
  • Impaired nitric oxide modulation of myocardial oxygen consumption in genetically cardiomyopathic hamsters.
  • Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies.
  • Renal and vascular injury induced by exogenous angiotensin II is AT1 receptor-dependent.
  • Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats.
  • Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery.
  • Modulation of renal oxygen consumption by nitric oxide is impaired after development of congestive heart failure in dogs.
  • Angiotensin converting enzyme inhibitors and cough--a north Indian study.
  • Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme a reductase in cardiac Syndrome X: role of superoxide dismutase activity.
  • Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed.
  • Cis-trans isomerization of an angiotensin I-converting enzyme inhibitor. An enzyme kinetic and nuclear magnetic resonance study.
  • Significance of exaggerated natriuresis after angiotensin AT1 receptor blockade or angiotensin- converting enzyme inhibition in obese Zucker rats.
  • Differential effects of angiotensin AT1 and AT2 receptors on the expression, translation and function of the Na+-H+ exchanger and Na+-HCO3- symporter in the rat heart after myocardial infarction.
  • Decreased platelet aggregation during angiotensin-converting enzyme inhibitor therapy. Results of a pilot study
  • A South African pharmaco-economic analysis of the Acute lnfarction Ramipril Efficacy (AIRE) Study.
  • The African American Study of Kidney Disease and Hypertension (AASK): new findings.
  • Differential influences of angiotensin converting-enzyme inhibitors on the coronary circulation.
  • Rx drugs
  • Mechanism of the action of angiotensin-converting enzyme inhibitors on agonist-induced Ca2+ influx.
  • Ramipril prevents basal arterial constriction and enhanced myogenic tone in the femoral artery in mildly uraemic normotensive rats.
  • Activity of the renin-angiotensin-aldosterone system and its impact on the effectiveness of treatment of chronic heart failure in patients with pulmonary tuberculosis
  • Reduction of infarct size and remodeling after ramipril
  • Future perspectives and implications.
  • Effects of angiotensin-converting enzyme inhibitors and cosaar on quality of life of patients with pulmonary tuberculosis and chronic heart failure
  • Long-term effects of brief antihypertensive treatment on systolic blood pressure and vascular reactivity in young genetically hypertensive rats.
  • Significance of angiotensin converting enzyme (ACE) in coronary circulation
  • Ramipril Enhances Autonomic Control in Essential Hypertension: A Study Employing Spectral Analysis of Heart Rate Variation.
  • Efficacy and Safety of Ramipril in Hypertensive Single-Kidney Patients.
  • Angiotensin II stimulates cyclooxygenase-2 mRNA expression in renal tissue from rats with kidney failure.
  • Threshold sodium excretory and renal blood flow effects of angiotensin converting enzyme inhibition.
  • Rx drugs
  • Rx drugs
  • Ramipril improves hemodynamic recovery but not microvascular response to ischemia in spontaneously hypertensive rats.
  • Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits: I. Effect on progression of atherosclerosis and endothelial dysfunction.
  • Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits: II. Effect on regression of atherosclerosis and restoration of endothelial function.
  • Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study.
  • Investigation of inhibitory effect of ramipril on apoptosis in spontaneously hypertensive rats
  • Effect of ACE-inhibitor ramiprilat and AT1-receptor antagonist candesartan on cardiac norepinephrine release: comparison between ischemic and nonischemic conditions.
  • Acute antihypertrophic actions of bradykinin in the rat heart: importance of cyclic GMP.
  • Rx drugs
  • General inhibition of renocortical cyclooxygenase-2 expression by the renin-angiotensin system.
  • Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors.
  • Relative effects of alpha 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog.
  • Kinins mediate the antiproliferative effect of ramipril in rat carotid artery.
  • The effect of ramipril on albumin excretion in diabetes and hypertension: the role of increased lysosomal activity and decreased transforming growth factor-beta expression.
  • Differential effects of saralasin and ramiprilat, the inhibitors of renin-angiotensin system, on cerulein-induced acute pancreatitis.
  • Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.
  • Twenty-four hour changes in active and inactive renin after various oral doses of the converting enzyme inhibitor ramipril (HOE498) in normal man.
  • Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker.
  • Rx drugs
  • Square wave voltammetric determination of the angiotensin-converting enzyme inhibitors cilazapril, quinapril and ramipril in pharmaceutical formulations.
  • Lack of male-female differences in disposition and esterase hydrolysis of ramipril to ramiprilat in healthy volunteers after a single oral dose.
  • Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).
  • Thirst and brain angiotensin in cattle.
  • Converting enzyme inhibition in kinin-deficient brown Norway rats.
  • High-affinity binding of the converting enzyme inhibitor, ramiprilat, to isolated human glomeruli.
  • The renin-angiotensin system and ramipril, a new converting enzyme inhibitor.
  • Ramipril reduces albuminuria in diabetic rats fed a high protein diet.
  • Comparison of the effects of the dipeptidyl peptidase inhibitors captopril, ramipril, and enalapril on water intake and sodium appetite of Sprague-Dawley rats.
  • Effects of converting enzyme inhibitors: ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated heart.
  • Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril.
  • Attenuation of cyclosporine A-induced vascular toxicity by ramipril.
  • Effects of chronic treatment with ramipril, a new ACE blocking agent, on presynaptic sympathetic nervous system of SHR.
  • The nephroprotective effect of ramipril. Effect on blood pressure and metabolic control in insulin-treated patients with type-2 diabetes mellitus
  • Stimulation of endothelial autacoid formation by inhibitors of angiotensin-converting enzyme.
  • Renal medulla and bradykinin during the development of hypertension in SHR.
  • Interference with the autonomic nervous system by the converting enzyme inhibitor ramipril in conscious spontaneously hypertensive rats.
  • The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity.
  • The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators.
  • Long-term renal function in primary hypertension. An epidemiological and pathophysiological study.
  • Remission of high blood pressure reverses arterial potassium channel alterations.
  • Role of the kidney in primary hypertension: a renal transplantation study in rats.
  • Administration of maximal or median doses of drugs in cardiovascular diseases?
  • Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension.
  • Vascular and cardiac protection by ramipril in spontaneously hypertensive rats: prevention versus regression study.
  • Ramipril inhibition of rabbit (Oryctolagus cuniculus) small intestinal brush border membrane angiotensin converting enzyme.
  • High affinity binding of ramiprilat on isolated human glomeruli.
  • The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension.
  • Cardioprotection by ramiprilat in isolated rabbit hearts.
  • Efficacy and safety of ramipril (HOE 498) in the treatment of hypertension: dose finding study.
  • Renal artery stenosis rapidly enhances atrial natriuretic peptide gene expression.
  • Effects of endothelin receptor antagonism and angiotensin-converting enzyme inhibition on cardiac and renal remodeling in the rat.
  • Role of bradykinin in the reduction of left ventricular hypertrophy induced by angiotensin-converting enzyme inhibitors in spontaneously hypertensive rats.
  • Adding angiotensin II type 1 receptor blockade to angiotensin-converting enzyme inhibition limits myocyte remodeling after myocardial infarction.
  • Influence of ramipril on renal function in patients with chronic congestive heart failure.
  • Interaction between the renin-angiotensin system and insulin-like growth factor I in aorto-caval fistula-induced cardiac hypertrophy in rats.
  • Ramipril and cardiac and renal angiotensin converting enzyme
  • Beta-blockade improves adjacent regional sympathetic innervation during postinfarction remodeling.
  • Converting enzyme inhibitor ramipril stimulates prostacyclin synthesis by isolated rat aorta: evidence for a kinin-dependent mechanism.
  • Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril.
  • ACE inhibition facilitates sodium and water excretion during PEEP in conscious volume-expanded dogs.
  • Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide.
  • Modulation of presynaptic sympathetic activity by kinins and related compounds: influence of converting enzyme inhibition.
  • Tissue renin-angiotensin system. Physiology and physiopathological value of their inhibition by ramipril
  • Effect of ramipril on the glucose/insulin coefficient and the ventricular mass index in patients with light to moderate arterial hypertension
  • Effect of bradykinin on systemic and pulmonary hemodynamics in the human
  • Cardiovascular effects of the converting enzyme inhibitor ramipril (HOE 498) in anesthetized dogs with acute ischemic left ventricular failure.
  • Effects of candesartan on the renin system in conscious rats.
  • Antihypertensive action of the converting enzyme inhibitor perindopril (S9490-3) in spontaneously hypertensive rats: comparison with enalapril (MK421) and ramipril (Hoe498).
  • Myocardial fibrosis rather than hypertrophy induces diastolic dysfunction in renovascular hypertensive rats.
  • Role of endothelium-derived bradykinin in the control of vascular tone.
  • Effects of chronic ramipril treatment in streptozotocin-induced diabetic rats.
  • What is the appropriate treatment for myocardial infarction with left ventricular dysfunction?
  • Regression of left ventricular hypertrophy under ramipril treatment investigated by nuclear magnetic resonance imaging.
  • Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats.
  • Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production.
  • ACE inhibition reduces left ventricular mass independent of pressure without affecting coronary flow and flow reserve in spontaneously hypertensive rats.
  • Local inhibition of bradykinin degradation in ischemic hearts.
  • Ramiprilat increases bradykinin outflow from isolated hearts of rat.
  • Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans.
  • Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
  • Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.
  • Biosynthesis of catecholamines and sympathetic outflow in spontaneously hypertensive rats (SHR) after chronic treatment with CE blocking agents.
  • Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
  • Role of bradykinin in chronic antihypertensive actions of ramipril in different hypertension models.
  • Mechanical strain and collagen potentiate mitogenic activity of angiotensin II in rat vascular smooth muscle cells.
  • Ramipril in elderly patients with mild and moderate hypertension. Clinical efficacy, effect on cerebral blood flow and intellectual functioning
  • Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man.
  • The role of angiotensin converting enzyme and nitric oxide in the enhanced systemic depressor responses to bradykinin in pregnant rats.
  • Influence of local converting enzyme inhibition on angiotensin and bradykinin effects in ischemic rat hearts.
  • Effect of angiotensin converting enzyme inhibitors on cardiac noradrenaline release.
  • Effects of the angiotensin converting enzyme inhibitor, ramipril, in isolated ischaemic rat heart are abolished by a bradykinin antagonist.
  • Role of nitric oxide in the control of cardiac oxygen consumption in B(2)-kinin receptor knockout mice.
  • Assay of tissue angiotensin converting enzyme.
  • Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure:the effects of ramipril, nifedipine and moxonidine.
  • Quantitative assessment of daily physical activity levels in patients with chronic heart failure by measuring energy expenditure--effects of converting enzyme inhibitor therapy.
  • Extracellular matrix deposition in hypertensive hearts antifibrotic effects of ramipril.
  • Mast cell infiltration and chemokine expression in progressive renal disease.
  • Ramiprilat prevents the development of acute coronary endothelial dysfunction in the dog.
  • Renal tissue angiotensins during converting enzyme inhibition of angiotensin I in spontaneously hypertensive rat
  • Renal tissue angiotensins during converting enzyme inhibition in the spontaneously hypertensive rat.
  • Kinetics, safety, and efficacy of ramipril after long-term administration in hemodialyzed patients.
  • Biosensors for the enantioselective analysis of S-enalapril and S-ramipril.
  • Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet.
  • Angiotensin converting enzyme in brush-border membranes of avian small intestine.
  • Angiotensin-converting enzyme inhibition during development alters calcium regulation in adult hypertensive rats.
  • Angiotensin-converting enzyme inhibition limits dysfunction in adjacent noninfarcted regions during left ventricular remodeling.
  • Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats.
  • Angiotensin II-dependent increased expression of Na+-glucose cotransporter in hypertension.







    DreamPharm: Herbal and Nutritional supplements online || Hair Million herbal formula for hair loss and hair growth || Wellstreet online pharmacy for click-order prescription medications || Altace Online Pharmacy || Rx Drugs USA, Prescription Drugs Online Pharmacy || Insurance plans and information || Insurance policies for all purposes || Antibiotics and prescription medications online literature ||